Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Adjuvante behandeling pancreascarcinoom: FOLFIRINOX of gemcitabine?
mrt 2019 | Maag-darm-leveroncologie